Does Semaglutide Cause Muscle Loss? A Chattanooga Doctor Explains

If you’re in Chattanooga or Signal Mountain and you’re Googling this before you start semaglutide, you’re asking the right question before the wrong one. Most people ask “how much weight will I lose.” Fewer ask what kind of weight. I’m Paul Miranda, MD — a board-certified family medicine physician, and at Summit Metabolic Health I review every chart myself. Here’s the honest answer on muscle.

Semaglutide is a GLP-1 receptor agonist. It doesn’t burn fat directly. It slows gastric emptying and acts on satiety circuits in the hypothalamus, so you feel full sooner and stay full longer. In the STEP 1 trial (NEJM 2021), that mechanism produced an average weight loss around 15% of body weight over 68 weeks. SURMOUNT-1, studying the dual-agonist tirzepatide, showed an even larger effect through a related pathway. Both trials measured total weight lost — not what kind of tissue it came from.

That distinction matters. A caloric deficit, however you get there, pulls from fat stores and from muscle. Semaglutide doesn’t target fat and spare muscle by design. It creates the deficit; your body decides where the weight comes from, and without intervention, some of it comes from lean mass.

The scale can’t tell you what you lost. Two patients can both drop 20 pounds — one mostly fat, one with a meaningful chunk of muscle — and the scale reads identical. The second patient’s resting metabolic rate drops further, strength declines, and the weight is more likely to come back as fat once the medication stops or the dose plateaus. That’s the actual risk worth asking about before you start: not “will I lose weight,” but “will I lose the right kind.”

This is also an age and activity question. A sedentary patient with little resistance training going into treatment has less muscle to protect and loses it faster under a deficit. A patient already lifting and eating adequate protein has more reserve and a different trajectory. The medication is the same. The outcome isn’t.

Across GLP-1 weight-loss trials, roughly a quarter to a third of total weight lost on semaglutide is lean mass, not fat — a pattern that shows up consistently in body-composition substudies of STEP and SURMOUNT data. That’s not a reason to avoid the medication. It’s in the same range as lean-mass loss seen with bariatric surgery and aggressive diet-only weight loss. It’s a reason to manage the deficit deliberately instead of treating the prescription as the whole plan.

The encouraging part: that ratio isn’t fixed. Resistance training and adequate protein intake during weight loss measurably shift how much of the loss comes from fat versus muscle. The biology doesn’t force a bad outcome. It just doesn’t prevent one on its own — someone has to build the counter-pressure in.

Age changes the stakes further. Lean mass declines with age on its own, even without a GLP-1 in the picture. A patient in their 50s or 60s starting semaglutide is layering a medication-driven deficit on top of a baseline decline that was already underway. That’s not a reason to wait. It’s a reason the protein target and the strength-training plan need to be set from week one, not added later after a scan shows the loss already happened.

This is where a prescription stops being enough. At Summit, your dose titration isn’t the only thing I’m watching. I set a protein target with you — generally in the range that supports muscle retention during a deficit, adjusted for your weight and activity — and I give you specific strength-training guidance, not a generic “stay active” line. If your energy or strength is dropping faster than expected, that’s a signal to slow titration, not just push through it.

None of that happens by accident. It happens because a physician is reviewing your chart across visits, not just approving a refill. We covered what that monitoring looks like week to week in your first month on a GLP-1 — titration, side effects, and the check-ins that catch problems before they compound. Muscle protection is one more thing that monitoring is for.

I also watch the pace of titration itself. Moving to the next dose before you’ve stabilized on the current one doesn’t just raise your odds of GI side effects — it can suppress appetite faster than you can adjust your protein intake to compensate. Slowing that climb when your intake or energy says you need it is a judgment call, not a form field. That’s the part a script can’t do.

Ro, Hims and Hers, Found, Henry Meds, and Calibrate all run on the same basic model: an intake form, a prescription, and a refill queue. There’s no named prescriber reviewing your chart longitudinally, and there’s no body-composition check built into the process. Nobody on the other end is watching whether your strength is holding up or just counting whether the vial shipped.

That’s not a knock on the medication they’re prescribing — it’s usually the same semaglutide or tirzepatide I prescribe. The difference is what happens between doses. A script refilled on autopilot has no mechanism to notice lean-mass loss, let alone correct for it. We laid out that structural gap in more detail in physician-supervised care versus a telehealth mill, and it applies directly here: a queue can renew your prescription. It can’t coach your protein intake or adjust your plan when your chart tells it to.

The GI side of this matters too, for a different reason — nausea and appetite suppression that go unmanaged can push protein intake down right when you need it most. We cover how a physician-led program handles that in GLP-1 side effects and how a physician-led program manages them. It’s one more place where someone needs to actually be looking at your case.

Before you start, ask whoever is prescribing:

– Will a physician review my chart directly, or is this a form-and-ship process? – What protein target should I be hitting during treatment, and does that change as my dose increases? – Is there specific strength-training guidance, or just a general “stay active” note? – Who adjusts my plan if I’m losing strength faster than expected — and how would either of us know? – What’s the plan for maintaining muscle after I reach goal weight, not just maintaining the weight loss?

If the honest answer to most of those is “I don’t know” or “nobody,” that’s the gap. The medication can get you most of the way to your weight goal. It takes a person paying attention to make sure what you lose is fat. You can read more on how we think about this across the broader GLP-1 picture on the Summit Metabolic Health blog.

Semaglutide doesn’t cause muscle loss on its own — an unmanaged caloric deficit does, and semaglutide creates that deficit. The fix isn’t avoiding the medication. It’s protein, resistance training, and a physician actually watching for it. Ready to start? Apply at summitmetabolichealth.com/apply.

This post is educational and does not replace a one-on-one medical evaluation. Individual results vary. Dr. Paul Miranda is a board-certified family medicine physician practicing telehealth at Summit Metabolic Health in Chattanooga, TN.